Speech-Language Pathologists in Brookland, AR Accepting Medicare
7 Speech-Language Pathologists found. Showing 1 - 7
 Kimberly Dawn Shelby, MCD, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 105 N Oak St, Brookland, AR 72417 Phone: 870-935-7809 |
Lesa Oxford Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 220 N Oak St, Brookland, AR 72417 Phone: 870-932-2080 Fax: 870-974-9760 |
Mrs. Melissa Conaway, MCD, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 220 N Oak St, Brookland, AR 72417 Phone: 870-932-2080 Fax: 870-974-9760 |
 Blooming Tree Therapy, Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 115 Cherry St, Brookland, AR 72417 Phone: 870-336-2778 Fax: 870-336-9055 |
Gracyn Michelle Garner, MCD, CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 220 N Oak St, Brookland, AR 72417 Phone: 870-932-2080 |
Angela Marie Shipman, MCD, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 220 N Oak St, Brookland, AR 72417 Phone: 870-926-9247 Fax: 870-974-9760 |
Innovative Medical Speech Language Pathology And Rehab Services, Inc. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 105 N Oak St, Brookland, AR 72417 Phone: 870-497-0326 |
News Archive
Oral contraceptives impair muscle mass gains in young women
Many active young women use oral contraceptives (OC) yet its effect on their body composition and exercise performance has not been thoroughly studied.
Study aims at best way to treat deep vein thrombosis
Patients who have a clot in their legs and are considering whether to be treated with traditional blood-thinning medication or undergo a minimally-invasive catheter-based clot removal procedure should feel comfortable that there is no difference in death rates between the two treatments, although there are more bleeding risks with the catheter procedure, according to a study by Temple University School of Medicine researchers.
OBN, ABPI sign MoU to build a better public profile
13 October 2014, London and Oxford: The ABPI, which represents large, medium and small innovative research-based biopharmaceutical companies in the UK and OBN, the membership organisation that brings together the UK's emerging life sciences companies, corporate partners and investors are delighted to announce their commitment to working together under a Memorandum of Understanding (MoU).
COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials
A new study, released as a preprint on the bioRxiv* server, describes the late-stage clinical trial efficacy of a new vaccine candidate based on a deoxyribonucleic acid (DNA) plasmid platform expressing the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Among different constructs of the vaccine plasmid, the RBD was found to produce the most potent and broad immune response.
› Verified 5 days ago